Article
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis.
Antimicrobial agents and chemotherapy - 1 Jun 2018
Ghannoum M, Long L, Larkin E L, Isham N, Sherif R, Borroto-Esoda K, Barat S, Angulo D
Abstract excerpt
Invasive aspergillosis remains a major cause of death among the immunocompromised population and those receiving long-term immunosuppressive therapy. In light of increased azole resistance, variable outcomes with existing echinocandin monotherapy and combination therapy, and persistent high mortality rates, new antifungal agents for the treatment of invasive aspergillosis are clearly needed. SCY-078 is the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.